MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

24.49 1.49

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

24.42

Max

24.78

Põhinäitajad

By Trading Economics

Sissetulek

50M

-42M

Müük

12M

178M

Kasumimarginaal

-23.615

Töötajad

705

EBITDA

50M

-30M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+50.08% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. okt 2025

Turustatistika

By TradingEconomics

Turukapital

692M

3B

Eelmine avamishind

23

Eelmine sulgemishind

24.49

Uudiste sentiment

By Acuity

30%

70%

67 / 371 Pingereas Healthcare

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. okt 2025, 18:13 UTC

Suurimad hinnamuutused turgudel

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17. okt 2025, 17:05 UTC

Suurimad hinnamuutused turgudel

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18. okt 2025, 13:30 UTC

Omandamised, ülevõtmised, äriostud

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18. okt 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

18. okt 2025, 07:00 UTC

Tulu

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17. okt 2025, 23:25 UTC

Omandamised, ülevõtmised, äriostud

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17. okt 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17. okt 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17. okt 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17. okt 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17. okt 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17. okt 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17. okt 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. okt 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17. okt 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17. okt 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17. okt 2025, 16:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

17. okt 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. okt 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17. okt 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17. okt 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17. okt 2025, 15:56 UTC

Tulu

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17. okt 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

50.08% tõus

12 kuu keskmine prognoos

Keskmine 36.8 USD  50.08%

Kõrge 60 USD

Madal 18 USD

Põhineb 17 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

17 ratings

10

Osta

6

Hoia

1

Müü

Sentiment

By Acuity

67 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
help-icon Live chat